

NOTE TO EDITORS

Most Favored Nation (MFN) : the members of the French-Danish Health Alliance, ALK, LEO Pharma, Lundbeck and Novo Nordisk call for an open, structured and constructive dialogue, a task force to coordinate all stakeholders on this issue in France, in order to assess the potential implications of the MFN for patients, public policies and the pharmaceutical industry, and to identify appropriate responses and courses of action.

In light of the potential implications of the US “Most Favored Nation” (MFN) policy, the French-Danish Health Alliance would like to contribute to the dialogue in France, bringing together the government and public authorities, stakeholders from the healthcare, research and innovation sectors, patient organisations and representatives of the pharmaceutical industry.

At a time of growing global competition and increasing challenges to Europe’s attractiveness, its capacity for innovation, and health sovereignty, such a collective discussion would help anticipate the potential consequences of MFN on investment, research and clinical trials, security of supply, and patients’ access to innovative treatments.

The Danish Government has set up a task force under the responsibility of the Ministry of Health to strengthen knowledge-sharing and dialogue, and to focus on possible proposals that could address the consequences associated with the MFN policy. The first meeting of this Task Force took place on 28 August 2026. It brought together several ministries and public authorities, representatives of the pharmaceutical industry, and patient organisations. Its mandate, composition, objectives, and work schedule have been made public (<https://www.ism.dk/nyheder/2026/juli/ny-taskforce-for-most-favoured-nation-paa-plads>) in order to assess the consequences of MFN and identify possible policy responses at both the Danish and European levels.

The Alliance believes that this approach, involving all stakeholders, could usefully contribute to the discussion in France. Without prejudging the format chosen by the French authorities to organise this national dialogue on the subject, the Alliance could contribute to it by sharing the lessons learnt by the Danish Task Force, while also helping to reduce uncertainty across the healthcare ecosystem in both countries.

As a think tank bringing together French-Danish healthcare companies operating in France, the Alliance is dedicated to facilitating dialogue and the exchange of perspectives between Denmark and France. Building on this role, it stands ready to contribute, alongside French stakeholders, to a constructive discussion on the implications of MFN, in particular by sharing lessons learnt from Danish experiences.

The French-Danish Health Alliance is a think tank that promotes dialogue on health policy and industrial policy issues. Established in 2019 by the Danish Embassy in France, it brings together four Danish pharmaceutical companies operating in France: ALK, LEO Pharma, Lundbeck and Novo Nordisk, which employ 4,500 people and operate five production sites across France. The Alliance has two main objectives: to improve access to treatments for patients with chronic diseases and to contribute to the development and strengthening of the life sciences sector in France. Through its analyses, recommendations and the sharing of Danish experiences, the Alliance contributes to the public debate on health policy and supports discussions on innovative and sustainable models.

The US MFN (‘Most Favoured Nation’) clause is a policy on medicine pricing launched by President Donald Trump on 12 May 2025. It aims to bring the prices of certain medicines in the United States into line with the lowest prices charged in selected OECD countries.

